Previous close | 6.27 |
Open | 6.32 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.33 - 6.32 |
52-week range | 4.05 - 9.94 |
Volume | |
Avg. volume | 49,685 |
Market cap | 98.166M |
Beta (5Y monthly) | -0.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.98 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 24 May 2022 |
1y target est | 20.00 |
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a criti